Waterjet surgery for BPH under the microscope: 3,000-Patient registry launches

NCT ID NCT07430423

Not yet recruiting Knowledge-focused Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This registry will follow 3,000 men with benign prostatic hyperplasia (BPH) who undergo Aquablation, a waterjet-based procedure to remove excess prostate tissue. Researchers will collect data from medical records to evaluate how well the procedure improves urinary symptoms and its safety. No extra tests or visits are required beyond standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aquablation (waterjet ablation) procedure
What this could lead to: If successful, this registry could provide real-world evidence on how well Aquablation works for BPH and help identify which patients benefit most.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care or data quality.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BENIGN PROSTATIC HYPERPLASIA (BPH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BENIGN PROSTATIC HYPERPLASIA (BPH)

Contacts and locations

Locations

The University of Chicago

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.